Diaceutics PLC (LON:DXRX – Get Free Report) insider Nick Roberts acquired 113 shares of Diaceutics stock in a transaction dated Wednesday, August 28th. The shares were bought at an average cost of GBX 134 ($1.77) per share, with a total value of £151.42 ($199.68).
Nick Roberts also recently made the following trade(s):
- On Friday, June 28th, Nick Roberts acquired 122 shares of Diaceutics stock. The shares were bought at an average cost of GBX 1 ($0.01) per share, with a total value of GBX 122 ($1.61).
Diaceutics Stock Performance
DXRX opened at GBX 132.50 ($1.75) on Friday. The firm has a market cap of £111.91 million, a PE ratio of -6,537.50 and a beta of 0.57. The business has a fifty day simple moving average of GBX 127.85 and a 200-day simple moving average of GBX 114.81. The company has a quick ratio of 9.92, a current ratio of 6.40 and a debt-to-equity ratio of 2.95. Diaceutics PLC has a fifty-two week low of GBX 82 ($1.08) and a fifty-two week high of GBX 136 ($1.79).
Analysts Set New Price Targets
View Our Latest Analysis on DXRX
About Diaceutics
Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.
See Also
- Five stocks we like better than Diaceutics
- What Are Trending Stocks? Trending Stocks Explained
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- What is MarketRank™? How to Use it
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- How to buy stock: A step-by-step guide for beginners
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for Diaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diaceutics and related companies with MarketBeat.com's FREE daily email newsletter.